ELEGANCE Registry Reports 12-Month Eluvia DES Outcomes in Complex PAD

October 16, 2026—The ELEGANCE registry, which focuses on historically underrepresented populations to generate real-world evidence, evaluated endovascular treatment of peripheral artery disease (PAD) with the Ranger drug-coated balloon or Eluvia drug-eluting stent (DES; both Boston Scientific Corporation).

PROMISE III Reports 1-Year Outcomes With TADV Using the LimFlow System

October 16, 2026—One-year results from the prospective, multicenter, single-arm PROMISE III trial evaluated transcatheter arterialization of the deep veins (TADV) with the LimFlow system (Stryker Peripheral Vascular) in patients with chronic limb-threatening ischemia (CLTI).

Esprit BTK Post-Approval Study Reports 6-Month Outcomes

October 16, 2026—Six-month results from Esprit BTK PAS were reported in patients with chronic limb-threatening ischemia (CLTI) treated with the Esprit below-the-knee (BTK) drug-eluting resorbable scaffold (DRS; Abbott).

HI-PEITHO Analysis Studies Predictors of Major Bleeding in Acute Intermediate-Risk PE

October 16, 2026—A post hoc analysis of the randomized HI-PEITHO study examined potential predictors of major bleeding in patients with acute intermediate-risk pulmonary embolism (PE) treated with ultrasound-facilitated catheter-directed thrombolysis (USCDT) using the Ekos endovascular system (Boston Scientific Corporation) plus anticoagulation (AC) or anticoagulation (AC) alone.

POWER PAD II Study of Pulse IVL System Meets Endpoints

October 16, 2026—Results from the prospective, single-arm, multicenter POWER PAD II study demonstrated that the Pulse intravascular lithotripsy (IVL) system (Amplitude Vascular Systems, Inc., recently acquired by Stryker) met its primary safety and effectiveness endpoints in patients with calcified femoropopliteal artery disease.

BOLT-DVT Evaluates CAVT With Penumbra’s Indigo Aspiration System

October 16, 2026—A study of computer-assisted vacuum thrombectomy (CAVT) met its predefined primary effectiveness and safety endpoints for the treatment of patients with deep vein thrombosis (DVT).

SUCCESS PTA Evaluates Cordis Selution SLR DEB at 24 Months

October 15, 2026—The 24-month data from the entire cohort of the SUCCESS PTA study were presented by Thomas Zeller, MD, in a late-breaking clinical trials session at VIVA 2026, the Vascular Interventional Advances conference.

Concept Medical’s MagicTouch Balloon Shows Low TLR and MALE Rates in Analysis From SirPAD Trial

October 15, 2026—A secondary analysis of the randomized SirPAD trial demonstrated lower rates of target-lesion revascularization (TLR) and major adverse limb events (MALE) at 1 year with the MagicTouch sirolimus-coated balloon (Concept Medical) for percutaneous transluminal angioplasty compared with standard uncoated balloon angioplasty in patients with femoropopliteal peripheral artery disease without tissue loss.